SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

SCYNEXIS (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines for difficult-to-treat and drug-resistant infections, has announced its participation in the H. C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, in New York City.

David Angulo, M.D., President and CEO of SCYNEXIS, will deliver a corporate presentation at 10:00 A.M. ET and will be available for one-on-one meetings with investors. Interested parties can request meetings through their H.C. Wainwright representative. The presentation will also be accessible via a live webcast, providing an opportunity for remote participation.

JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will make a corporate presentation as well as host 1x1 meetings at the H. C. Wainwright 26^th Annual Global Investment Conference on Wednesday, September 11 at 10:00 A.M. ET.

H. C. Wainwright 26^th Annual Global Investment Conference

Format:	Live presentation and one-on-one meetings
Date:	Wednesday, September 11, 2024
Time:	10:00 A.M. ET
Location:	New York, NY
Webcast:	Link

To request a one-on-one meeting with management, please reach out to your H.C. Wainwright representative.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps”. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME^® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

FAQ

When is SCYNEXIS (SCYX) presenting at the H. C. Wainwright Global Investment Conference?

SCYNEXIS (SCYX) is presenting at the H. C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024, at 10:00 A.M. ET.

Who will be representing SCYNEXIS (SCYX) at the H. C. Wainwright conference?

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS, will be representing the company at the H. C. Wainwright conference.

What type of meetings will SCYNEXIS (SCYX) be hosting at the investment conference?

SCYNEXIS (SCYX) will be hosting one-on-one meetings with investors at the H. C. Wainwright 26th Annual Global Investment Conference.

Where is the H. C. Wainwright Global Investment Conference being held?

The H. C. Wainwright 26th Annual Global Investment Conference is being held in New York, NY.

Will there be a webcast of SCYNEXIS's (SCYX) presentation at the conference?

Yes, there will be a webcast of SCYNEXIS's (SCYX) presentation at the H. C. Wainwright conference. A link to the webcast will be provided.